 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CAPTOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CAPTOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Hydrochlorothiazide : Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology [0m
[31mProgram [0m[1;31m([0m[31mNTP[0m[1;31m)[0m[31m uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice [0m[1;31m([0m[31mat doses of up to approximately [0m[1;31m600[0m[31m mg/kg/day[0m[1;31m)[0m[31m or in male and female rats [0m[1;31m([0m[31mat doses of up to [0m
[31mapproximately [0m[1;31m100[0m[31m mg/kg/day[0m[1;31m)[0m[31m. The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice. Hydrochlorothiazide was not genotoxic in in vitro assays using strains TA [0m[1;31m98[0m[31m, TA [0m[1;31m100[0m[31m, [0m
[31mTA [0m[1;31m1535[0m[31m, TA [0m[1;31m1537[0m[31m and TA [0m[1;31m1538[0m[31m of Salmonella typhimurium [0m[1;31m([0m[31mAmes assay[0m[1;31m)[0m[31m and in the Chinese Hamster Ovary [0m[1;31m([0m[31mCHO[0m[1;31m)[0m[31m test for chromosomal aberrations, or in vivo assays using mouse germinal cell chromosomes, [0m
[31mChinese hamster bone marrow chromosomes, and the Drosophilia sex linked recessive lethal trait gene. CAPTOPRIL: precautions: Positive test results were obtained only in the in vitro CHO Sister [0m
[31mChromatid Exchange [0m[1;31m([0m[31mclastogenicity[0m[1;31m)[0m[31m and in the Mouse Lymphoma Cell [0m[1;31m([0m[31mmutagenicity[0m[1;31m)[0m[31m assays, using concentrations of hydrochlorothiazide from [0m[1;31m43[0m[31m to [0m[1;31m1300[0m[31m mcg/mL, and in the Aspergillus nidulans [0m
[31mnon-disjunction assay at an unspecified concentration. Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via [0m
[31mtheir diet, to doses of up to [0m[1;31m100[0m[31m and [0m[1;31m4[0m[31m mg/kg, respectively, prior to conception and throughout gestation. Animal Toxicology Captopril : Chronic oral toxicity studies were conducted in rats [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m,[0m
[31mdogs [0m[1;31m([0m[1;31m47[0m[31m weeks; [0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m, mice [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m, and monkeys [0m[1;31m([0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m. Significant drug-related toxicity included effects on hematopoiesis, renal toxicity, erosion/ulceration of the stomach, and variation of [0m
[31mretinal blood vessels. CAPTOPRIL: precautions: Reductions in hemoglobin and/or hematocrit values were seen in mice, rats, and monkeys at doses [0m[1;31m50[0m[31m to [0m[1;31m150[0m[31m times the maximum recommended human dose [0m
[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m. Anemia, leukopenia, thrombocytopenia, and bone marrow suppression occurred in dogs at doses [0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times MRHD. The reductions in hemoglobin and hematocrit values in rats and mice were only [0m
[31msignificant at [0m[1;31m1[0m[31m year and returned to normal with continued dosing by the end of the study. Marked anemia was seen at all dose levels [0m[1;31m([0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times MRHD[0m[1;31m)[0m[31m in dogs, whereas moderate to marked [0m
[31mleukopenia was noted only at [0m[1;31m15[0m[31m and [0m[1;31m30[0m[31m times MRHD and thrombocytopenia at [0m[1;31m30[0m[31m times MRHD. The anemia could be reversed upon discontinuation of dosing. CAPTOPRIL: precautions: Bone marrow suppression [0m
[31moccurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the [0m[1;31m1[0m[31m year study. However, in the [0m[1;31m47[0m[31m-week study at a dose [0m[1;31m30[0m[31m times MRHD, bone [0m
[31mmarrow suppression was found to be reversible upon continued drug administration. Captopril caused hyperplasia of the juxtaglomerular apparatus of the kidneys at doses [0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times the MRHD in rats [0m
[31mand mice, at [0m[1;31m20[0m[31m to [0m[1;31m60[0m[31m times MRHD in monkeys, and at [0m[1;31m30[0m[31m times the MRHD in dogs. Gastric erosions/ulcerations were increased in incidence at [0m[1;31m20[0m[31m and [0m[1;31m200[0m[31m times MRHD in male rats and at [0m[1;31m30[0m[31m and [0m[1;31m65[0m[31m times [0m
[31mMRHD in dogs and monkeys, respectively. Rabbits developed gastric and intestinal ulcers when given oral doses approximately [0m[1;31m30[0m[31m times MRHD for only five to seven days. CAPTOPRIL: precautions: In the [0m
[31mtwo-year rat study, irreversible and progressive variations in the caliber of retinal vessels [0m[1;31m([0m[31mfocal sacculations and constrictions[0m[1;31m)[0m[31m occurred at all dose levels [0m[1;31m([0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times MRHD[0m[1;31m)[0m[31m in a dose-related[0m
[31mfashion. The effect was first observed in the [0m[1;31m88[0m[31m th week of dosing, with a progressively increased incidence thereafter, even after cessation of dosing. Pregnancy Categories C [0m[1;31m([0m[31mfirst trimester[0m[1;31m)[0m[31m and D [0m
[1;31m([0m[31msecond and third trimesters[0m[1;31m)[0m[31m: See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality . Pregnancy: Nonteratogenic Effects: Hydrochlorothiazide : Thiazides cross the placental barrier and [0m
[31mappear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, [0m
[31mthrombocytopenia, and possibly other adverse reactions which have occurred in the adult. CAPTOPRIL: precautions: Nursing Mothers Both captopril and hydrochlorothiazide are excreted in human milk. [0m
[31mBecause of the potential for serious adverse reactions in nursing infants from both drugs, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the [0m
[31mimportance of captopril and hydrochlorothiazide to the mother. [0m[1;31m([0m[31mSee PRECAUTIONS: Pediatric Use. [0m[1;31m)[0m[31m Pediatric Use Safety and effectiveness in pediatric patients have not been established. There is [0m
[31mlimited experience reported in the literature with the use of captopril in the pediatric population; dosage, on a weight basis, was generally reported to be comparable to or less than that used in [0m
[31madults. Infants, especially newborns, may be more susceptible to the adverse hemodynamic effects of captopril. Excessive, prolonged and un-predictable decreases in blood pressure and associated [0m
[31mcomplications, including oliguria and seizures, have been reported. CAPTOPRIL: precautions: Captopril and hydrochlorothiazide should be used in pediatric patients only if other measures for [0m
[31mcontrolling blood pressure have not been effective.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: warnings: Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of treatment; some cases required medical [0m
[31mtherapy. [0m[1;31m([0m[31mSee PRECAUTIONS: Information for Patients and ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. CAPTOPRIL: warnings: Anaphylactoid Reactions During Desensitization : Two patients undergoing desensitizing treatment with [0m
[31mhymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, [0m
[31mbut they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure : Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and [0m
[31mtreated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. [0m
[31mNeutropenia/Agranulocytosis : Neutropenia [0m[1;31m([0m[31m< [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m with myeloid hypoplasia has resulted from use of captopril. CAPTOPRIL: warnings: About half of the neutropenic patients developed systemic or [0m
[31moral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient: In clinical trials in patients with [0m
[31mhypertension who have normal renal function [0m[1;31m([0m[31mserum creatinine less than [0m[1;31m1.6[0m[31m mg/dL and no collagen vascular disease[0m[1;31m)[0m[31m, neutropenia has been seen in one patient out of over [0m[1;31m8[0m[31m,[0m[1;31m600[0m[31m exposed. In patients [0m
[31mwith some degree of renal failure [0m[1;31m([0m[31mserum creatinine at least [0m[1;31m1.6[0m[31m mg/dL[0m[1;31m)[0m[31m but no collagen vascular disease, the risk of neutropenia in clinical trials was about [0m[1;31m1[0m[31m per [0m[1;31m500[0m[31m, a frequency over [0m[1;31m15[0m[31m times that[0m
[31mfor uncomplicated hypertension. Daily doses of captopril were relatively high in these patients, particularly in view of their diminished renal function. CAPTOPRIL: warnings: In foreign marketing [0m
[31mexperience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated with neutropenia but this association has not appeared in U.S. reports. In patients with [0m
[31mcollagen vascular diseases [0m[1;31m([0m[31me.g., systemic lupus erythematosus, scleroderma[0m[1;31m)[0m[31m and impaired renal function, neutropenia occurred in [0m[1;31m3.7[0m[31m percent of patients in clinical trials. While none of the over [0m[1;31m750[0m
[31mpatients in formal clinical trials of heart failure developed neutropenia, it has occurred during the subsequent clinical experience. About half of the reported cases had serum creatinine â‰¥ [0m[1;31m1.6[0m[31m mg/dL [0m
[31mand more than [0m[1;31m75[0m[31m percent were in patients also receiving procainamide. In heart failure, it appears that the same risk factors for neutropenia are present. The neutropenia has usually been detected [0m
[31mwithin three months after captopril was started. CAPTOPRIL: warnings: Bone marrow examinations in patients with neutropenia consistently showed myeloid hypoplasia, frequently accompanied by erythroid [0m
[31mhypoplasia and decreased numbers of megakaryocytes [0m[1;31m([0m[31me.g., hypoplastic bone marrow and pancytopenia[0m[1;31m)[0m[31m; anemia and thrombocytopenia were sometimes seen. In general, neutrophils returned to normal in [0m
[31mabout two weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About [0m[1;31m13[0m[31m percent of the cases of neutropenia have ended fatally, but almost all [0m
[31mfatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. [0m
[31mEvaluation of the hypertensive or heart failure patient should always include assessment of renal function. CAPTOPRIL: warnings: If captopril is used in patients with impaired renal function, white [0m
[31mblood cell and differential counts should be evaluated prior to starting treatment and at approximately two-week intervals for about three months, then periodically. In patients with collagen vascular[0m
[31mdisease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of [0m
[31mbenefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m. If infection is suspected, white cell counts [0m
[31mshould be performed without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia [0m[1;31m([0m[31mneutrophil [0m
[31mcount < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m the physician should withdraw captopril and closely follow the patientâ€™s course. CAPTOPRIL: warnings: Proteinuria : Total urinary proteins greater than [0m[1;31m1[0m[31m g per day were seen in [0m
[31mabout [0m[1;31m0.7[0m[31m percent of patients receiving captopril. About [0m[1;31m90[0m[31m percent of affected patients had evidence of prior renal disease or received relatively high doses of captopril [0m[1;31m([0m[31min excess of [0m[1;31m150[0m[31m mg/day[0m[1;31m)[0m[31m, [0m
[31mor both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within six months whether or not captopril was continued. Parameters[0m
[31mof renal function, such as BUN and creatinine, were seldom altered in the patients with proteinuria. Hypotension : Excessive hypotension was rarely seen in hypertensive patients but is a possible [0m
[31mconsequence of captopril use in salt/volume depleted persons [0m[1;31m([0m[31msuch as those treated vigorously with diuretics[0m[1;31m)[0m[31m, patients with heart failure or those patients undergoing renal dialysis. [0m[1;31m([0m[31mSee [0m
[31mPRECAUTIONS: Drug Interactions .         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: pharm_class_pe         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: Nervous/Psychiatric : ataxia, confusion, depression, nervousness, somnolence. Respiratory : bronchospasm, eosinophilic pneumonitis, rhinitis. Special Senses : [0m
[31mblurred vision. Urogenital : impotence. As with other ACE inhibitors, a syndrome has been reported which may include: fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash or other [0m
[31mdermatologic manifestations, eosinophilia and an elevated ESR. Fetal/Neonatal Morbidity and Mortality: See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality . Hydrochlorothiazide : [0m
[31mGastrointestinal System : anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice [0m[1;31m([0m[31mintrahepatic cholestatic jaundice[0m[1;31m)[0m[31m, pancreatitis, and sialadenitis. CAPTOPRIL: [0m
[31madverse_reactions: Central Nervous System : dizziness, vertigo, paresthesias, headache, and xanthopsia. Hematologic : leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic [0m
[31manemia. Cardiovascular : orthostatic hypotension. Hypersensitivity : purpura, photosensitivity, rash, urticaria, necrotizing angiitis [0m[1;31m([0m[31mvasculitis; cutaneous vasculitis[0m[1;31m)[0m[31m, fever, respiratory distress [0m
[31mincluding pneumonitis, and anaphylactic reactions. Other : hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness, and transient blurred vision. Whenever adverse reactions are [0m
[31mmoderate or severe, thiazide dosage should be reduced or therapy withdrawn. CAPTOPRIL: adverse_reactions: Altered Laboratory Findings: Serum Electrolytes : Hyperkalemia: small increases in serum [0m
[31mpotassium, especially in patients with renal impairment [0m[1;31m([0m[31msee PRECAUTIONS: Captopril [0m[1;31m)[0m[31m. Hyponatremia : particularly in patients receiving a low sodium diet or concomitant diuretics. BUN/Serum [0m
[31mCreatinine : Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with renovascular hypertension may occur. Rapid reduction of longstanding or [0m
[31mmarkedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum creatinine. Hematologic : A positive ANA has been reported. [0m
[31mLiver Function Tests : Elevations of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred. CAPTOPRIL: adverse_reactions: Postmarketing Experience : Non-melanoma Skin Cancer : [0m
[31mHydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma [0m[1;31m([0m[31mSCC[0m[1;31m)[0m[31m [0m
[31mand in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately [0m[1;31m1[0m[31m additional case per [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients per year, and for white patients [0m
[31mtaking a cumulative dose of â‰¥ [0m[1;31m50[0m[31m,[0m[1;31m000[0m[31m mg the risk increase was approximately [0m[1;31m1[0m[31m additional SCC case for every [0m[1;31m6[0m[31m,[0m[1;31m700[0m[31m patients per year. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma [0m
[31mHoldings, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m- [0m[1;31m874[0m[31m-[0m[1;31m7464[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: precautions: The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior [0m
[31mto initiation of treatment with captopril or initiating therapy with small doses [0m[1;31m([0m[1;31m6.25[0m[31m or [0m[1;31m12.5[0m[31m mg[0m[1;31m)[0m[31m. Alternatively, provide medical supervision for at least one hour after the initial dose. If [0m
[31mhypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication[0m
[31mto further doses which can be given without difficulty once the blood pressure has increased after volume expansion. CAPTOPRIL: precautions: Agents Having Vasodilator Activity : Data on the effect of [0m
[31mconcomitant use of other vasodilators in patients receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates [0m[1;31m([0m[31mas used for management of angina[0m[1;31m)[0m[31m or other drugs [0m
[31mhaving vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower [0m
[31mdosage. Agents Causing Renin Release : Captoprilâ€™s effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics [0m[1;31m([0m[31me.g., thiazides[0m[1;31m)[0m[31m may activate the [0m
[31mrenin-angiotensin-aldosterone system. Agents Affecting Sympathetic Activity : The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril [0m
[31malone or with diuretics. Therefore, agents affecting sympathetic activity [0m[1;31m([0m[31me. CAPTOPRIL: precautions: ., ganglionic blocking agents or adrenergic neuron blocking agents[0m[1;31m)[0m[31m should be used with caution. [0m
[31mBeta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Agents Increasing Serum Potassium : Since captopril decreases [0m
[31maldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for [0m
[31mdocumented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution. CAPTOPRIL: [0m
[31mdrug_interactions: Gold : Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium [0m
[31maurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including captopril and hydrochlorothiazide tablets. Inhibitors of Endogenous Prostaglandin Synthesis : It has been reported that indomethacin may[0m
[31mreduce the antihypertensive effect of captopril, especially in cases of low renin hypertension. Other non-steroidal anti-inflammatory agents [0m[1;31m([0m[31me.g., aspirin[0m[1;31m)[0m[31m may also have this effect. Lithium : [0m
[31mIncreased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with [0m
[31mcaution and frequent monitoring of serum lithium levels is recommended. CAPTOPRIL: drug_interactions: If a diuretic is also used, it may increase the risk of lithium toxicity [0m[1;31m([0m[31msee PRECAUTIONS: Drug [0m
[31mInteractions: Hydrochlorothiazide: Lithium [0m[1;31m)[0m[31m. Hydrochlorothiazide : When administered concurrently the following drugs may interact with thiazide diuretics: Alcohol, Barbiturates, or Narcotics : [0m
[31mpotentiation of orthostatic hypotension may occur. Amphotericin B, Corticosteroids, or Corticotropin [0m[1;31m([0m[31mACTH[0m[1;31m)[0m[31m : may intensify electrolyte imbalance, particularly hypokalemia. Monitor potassium levels; [0m
[31muse potassium replacements if necessary. Anticoagulants [0m[1;31m([0m[31mOral[0m[1;31m)[0m[31m : dosage adjustments of anticoagulant medication may be necessary since hydrochlorothiazide may decrease their effects. Antigout [0m
[31mMedications : dosage adjustments of antigout medication may be necessary since hydrochlorothiazide may raise the level of blood uric acid. Other Antihypertensive Medications [0m[1;31m([0m[31me. CAPTOPRIL: [0m
[31mdrug_interactions: Drug Interactions: Captopril : Hypotensionâ€”Patients On Diuretic Therapy : Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as [0m
[31mthose on severe dietary salt restrictions or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of [0m
[31mcaptopril. The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of [0m
[31mtreatment with captopril or initiating therapy with small doses [0m[1;31m([0m[1;31m6.25[0m[31m or [0m[1;31m12.5[0m[31m mg[0m[1;31m)[0m[31m. Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the [0m
[31mpatient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. CAPTOPRIL: drug_interactions: This transient hypotensive response is not a [0m
[31mcontraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion. Agents Having Vasodilator Activity : Data on the effect of [0m
[31mconcomitant use of other vasodilators in patients receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates [0m[1;31m([0m[31mas used for management of angina[0m[1;31m)[0m[31m or other drugs [0m
[31mhaving vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower [0m
[31mdosage. Agents Causing Renin Release : Captoprilâ€™s effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics [0m[1;31m([0m[31me.g., thiazides[0m[1;31m)[0m[31m may activate the [0m
[31mrenin-angiotensin-aldosterone system. CAPTOPRIL: drug_interactions: Agents Affecting Sympathetic Activity : The sympathetic nervous system may be especially important in supporting blood pressure in [0m
[31mpatients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity [0m[1;31m([0m[31me.g., ganglionic blocking agents or adrenergic neuron blocking agents[0m[1;31m)[0m[31m should be used with [0m
[31mcaution. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Agents Increasing Serum Potassium : Since captopril [0m
[31mdecreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only [0m
[31mfor documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: clinical_pharmacology: Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity [0m[1;31m([0m[31mPRA[0m[1;31m)[0m[31m, the latter resulting from loss of negative feedback [0m
[31mon renin release caused by reduction in angiotensin II. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along [0m
[31mwith sodium and fluid loss. The antihypertensive effects persist for a longer period of time than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular [0m
[31mendothelium is inhibited longer than the ACE in circulating blood. Pharmacokinetics: After oral administration of therapeutic doses of captopril, rapid absorption occurs with peak blood levels at [0m
[31mabout one hour. The presence of food in the gastrointestinal tract reduces absorption by about [0m[1;31m30[0m[31m to [0m[1;31m40[0m[31m percent; captopril therefore should be given one hour before meals. Based on carbon-[0m[1;31m14[0m[31m labeling,[0m
[31maverage minimal absorption is approximately [0m[1;31m75[0m[31m percent. CAPTOPRIL: clinical_pharmacology: In a [0m[1;31m24[0m[31m-hour period, over [0m[1;31m95[0m[31m percent of the absorbed dose is eliminated in the urine; [0m[1;31m40[0m[31m to [0m[1;31m50[0m[31m percent is [0m
[31munchanged drug; most of the remainder is the disulfide dimer of captopril and captopril-cysteine disulfide. Approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m percent of the circulating drug is bound to plasma proteins. The [0m
[31mapparent elimination half-life for total radioactivity in blood is probably less than three hours. An accurate determination of half-life of unchanged captopril is not, at present, possible, but it is[0m
[31mprobably less than two hours. In patients with renal impairment, however, retention of captopril occurs [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Pharmacodynamics: Administration of captopril results in a [0m
[31mreduction of peripheral arterial resistance in hypertensive patients with either no change, or an increase, in cardiac output. There is an increase in renal blood flow following administration of [0m
[31mcaptopril and glomerular filtration rate is usually unchanged. CAPTOPRIL: clinical_pharmacology: In patients with heart failure, significantly decreased peripheral [0m[1;31m([0m[31msystemic vascular[0m[1;31m)[0m[31m resistance and [0m
[31mblood pressure [0m[1;31m([0m[31mafterload[0m[1;31m)[0m[31m, reduced pulmonary capillary wedge pressure [0m[1;31m([0m[31mpreload[0m[1;31m)[0m[31m and pulmonary vascular resistance, increased cardiac output, and increased exercise tolerance time [0m[1;31m([0m[31mETT[0m[1;31m)[0m[31m have been [0m
[31mdemonstrated. Reductions of blood pressure are usually maximal [0m[1;31m60[0m[31m to [0m[1;31m90[0m[31m minutes after oral administration of an individual dose of captopril. The duration of effect is dose related and is extended in [0m
[31mthe presence of a thiazide-type diuretic. The full effect of a given dose may not be attained for [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m weeks [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The blood pressure lowering effects of captopril and [0m
[31mthiazide-type diuretics are additive. In contrast, captopril and beta-blockers have a less than additive effect. Blood pressure is lowered to about the same extent in both standing and supine [0m
[31mpositions. CAPTOPRIL: clinical_pharmacology: Orthostatic effects and tachycardia are infrequent but may occur in volume-depleted patients. Abrupt withdrawal of captopril has not been associated with a[0m
[31mrapid increase in blood pressure. Studies in rats and cats indicate that captopril does not cross the blood-brain barrier to any significant extent. Hydrochlorothiazide : Thiazides affect the renal [0m
[31mtubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic potency. Thiazides increase excretion of sodium and chloride in [0m
[31mapproximately equivalent amounts. Natriuresis causes a secondary loss of potassium and bicarbonate. The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not affect normal[0m
[31mblood pressure. The mean plasma half-life of hydrochlorothiazide in fasted individuals has been reported to be approximately [0m[1;31m2.5[0m[31m hours. CAPTOPRIL: clinical_pharmacology: Onset of diuresis occurs in [0m
[31mtwo hours and the peak effect at about four hours. Its action persists for approximately six to twelve hours. Hydrochlorothiazide is eliminated rapidly by the kidney.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The information available in the CAPTOPRIL label does not directly address the risk of bleeding. However, it does mention hematologic adverse reactions such as neutropenia/agranulocytosis, [0m
[32manemia, thrombocytopenia, and pancytopenia. Thrombocytopenia, which is a decrease in the number of platelets in the blood, could potentially increase the risk of bleeding, although the label does not [0m
[32mexplicitly state that CAPTOPRIL increases the risk of bleeding.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: Hematologic : Neutropenia/agranulocytosis has occurred [0m[32m...[0m[32m thrombocytopenia, and pancytopenia.[0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The information available in the CAPTOPRIL label does not directly [0m
[34maddress the risk of bleeding. However, it does mention hematologic adverse reactions such as neutropenia/agranulocytosis, anemia, thrombocytopenia, and pancytopenia. Thrombocytopenia, which is a [0m
[34mdecrease in the number of platelets in the blood, could potentially increase the risk of bleeding, although the label does not explicitly state that CAPTOPRIL increases the risk of bleeding.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: Hematologic : Neutropenia/agranulocytosis has occurred [0m[34m...[0m[34m thrombocytopenia, and pancytopenia.[0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the CAPTOPRIL label does not directly address the risk of bleeding but does mention hematologic adverse reactions such as neutropenia/agranulocytosis, anemia, [0m
[32mthrombocytopenia, and pancytopenia."[0m[32m,[0m
[32m      [0m[32m"Thrombocytopenia, which is a decrease in the number of platelets in the blood, could potentially increase the risk of bleeding, although the label does not explicitly state that CAPTOPRIL [0m
[32mincreases the risk of bleeding."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The CAPTOPRIL label does not directly state that the drug increases the risk of bleeding. However, it does list thrombocytopenia as a potential adverse reaction, which could increase [0m
[32mthe risk of bleeding. The degree of risk associated with CAPTOPRIL in terms of causing bleeding is not specified in the label, and therefore, the relationship is not definitively established."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the CAPTOPRIL label does not directly address the risk of bleeding but does mention hematologic adverse reactions such as neutropenia/agranulocytosis, anemia, [0m
[34mthrombocytopenia, and pancytopenia."[0m[34m,[0m
[34m      [0m[34m"Thrombocytopenia, which is a decrease in the number of platelets in the blood, could potentially increase the risk of bleeding, although the label does not explicitly state that CAPTOPRIL [0m
[34mincreases the risk of bleeding."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The CAPTOPRIL label does not directly state that the drug increases the risk of bleeding. However, it does list thrombocytopenia as a potential adverse reaction, which could increase [0m
[34mthe risk of bleeding. The degree of risk associated with CAPTOPRIL in terms of causing bleeding is not specified in the label, and therefore, the relationship is not definitively established."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that the CAPTOPRIL label does not directly address the risk of bleeding but does mention hematologic adverse reactions such as neutropenia/agranulocytosis, anemia, [0m
[31mthrombocytopenia, and pancytopenia.[0m
[1;31m3[0m[31m. Thrombocytopenia, which is a decrease in the number of platelets in the blood, could potentially increase the risk of bleeding, although the label does not explicitly state that CAPTOPRIL increases[0m
[31mthe risk of bleeding.[0m
[31m        -----[0m
[31m        Final answer: The CAPTOPRIL label does not directly state that the drug increases the risk of bleeding. However, it does list thrombocytopenia as a potential adverse reaction, which could [0m
[31mincrease the risk of bleeding. The degree of risk associated with CAPTOPRIL in terms of causing bleeding is not specified in the label, and therefore, the relationship is not definitively established.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does CAPTOPRIL increase or decrease the risk of bleeding?"[0m[32m is as follows:[0m

[32mThe CAPTOPRIL label does not directly state that the drug increases the risk of bleeding. However, it does list thrombocytopenia as a potential adverse reaction, which could increase the risk of [0m
[32mbleeding. The degree of risk associated with CAPTOPRIL in terms of causing bleeding is not specified in the label, and therefore, the relationship is not definitively established.[0m
